Objective: The purpose of this study was to examine the in vitro activity of daptomycin using an optimal calcium (Ca 2+ ) concentration (50 mg/L) against a diverse collection of enterococcal and Staphylococcus aureus clinical isolates, including glycopeptide-resistant enterococci (GRE) and methicillin-resistant S. aureus (MRSA). Results: All staphylococcal isolates tested, and the majority of enterococcal isolates (96.5%), would be considered susceptible to daptomycin if the breakpoint previously proposed of ≤2 mg/L was applied. The activity of daptomycin against MRSA and methicillin-susceptible S. aureus was essentially equal. Daptomycin also had similar activity against GRE and glycopeptide-susceptible enterococci. Every S. aureus isolate had a daptomycin zone diameter ≥20 mm, and all of the enterococcal isolates had daptomycin zone diameters ≥17 mm.
Introduction
Daptomycin is an investigational cyclic lipopeptide antibiotic with a novel mechanism of action against Gram-positive organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-resistant enterococci (GRE), for which a limited number of effective therapeutic agents are available. 1 Although the bactericidal activity of daptomycin is not yet completely understood, interference with plasma membrane function appears to be an important effect. 1 When performing broth microdilution susceptibility testing, the activity of daptomycin is enhanced two-to four-fold by increasing the calcium (Ca 2+ ) concentration of Mueller-Hinton (MH) broth from the 20-25 mg/L concentration currently recommended by the NCCLS 2 to 50 mg/L-a level that more closely approximates the physiological Ca 2+ level of human serum. [3] [4] [5] [6] This higher 50 mg/L Ca 2+ level was recommended for MH broth by the NCCLS in 1985 standards, but subsequently lowered to achieve the optimal Ca 2+ level determined for accurate testing of aminoglycosides against Pseudomonas aeruginosa and tetracycline against all bacteria. 2, 7 Multiple investigators have recommended that physiological levels of Ca 2+ (45-55 mg/L) be used for broth dilution susceptibility testing of daptomycin. [3] [4] [5] [6] A recent study, examining the Ca 2+ dependence of daptomycin activity, suggests Ca 2+ binding by the lipopeptide antibiotic increases its hydrophobicity, enhancing interaction with cytoplasmic membrane bilayers. 8 The purpose of this study was to examine the in vitro activity of daptomycin, using broth microdilution with an optimal Ca 2+ concentration (50 mg/L), and compare it with the activities of other agents against a large, diverse collection of recent enterococcal and Staphylococcus aureus clinical isolates, including GRE and MRSA. A daptomycin zone diameter was also determined for each isolate 10 from 21 hospital laboratories in the USA and Canada.
MICs were determined according to NCCLS broth microdilution guidelines, 2 with one exception: cation-adjusted MH broth (Difco Laboratories, Detroit, MI, USA) was supplemented to a physiological level of 50 mg/L Ca 2+ when testing daptomycin. Two-fold serial dilutions of eight antimicrobials were tested: daptomycin (0.015-32 mg/L), quinupristin-dalfopristin (0.03-64 mg/L), linezolid (0.015-32 mg/L), vancomycin (0.06-128 mg/L), teicoplanin (0.06-128 mg/L), oxacillin (0.015-32 mg/L), erythromycin (0.12-128 mg/L) and clindamycin (0.03-32 mg/L). Resistance was defined according to NCCLS MIC interpretive standards. 11 A zone diameter was determined for each isolate with a 30 µg daptomycin disc (Cubist Pharmaceuticals, Inc., Lexington, MA, USA) according to NCCLS disc diffusion guidelines, 12 except for a higher Ca 2+ concentration (50 mg/L) in the MH agar (Remel, Lenexa, KS, USA). Daily quality control was performed using S. aureus ATCC 29213 (broth microdilution), S. aureus ATCC 25923 (disc diffusion) and E. faecalis ATCC 29212 (both methods).
Results
The daptomycin MICs for S. aureus ranged from 0.12-1 mg/L ( Table  1) . The daptomycin MICs, at which 90% of strains were inhibited (MIC 90 s) for methicillin-susceptible S. aureus (MSSA) and MRSA for daptomycin, were similar (0.25 mg/L and 0.5 mg/L, respectively), as were the MSSA and MRSA MIC 90 s of quinupristin-
For enterococci, the daptomycin MICs ranged from ≤0.015-4 mg/L. The activity of daptomycin against GRE was essentially the same as glycopeptide-susceptible enterococci (GSE). For E. faecium, the MIC 90 s of daptomycin and linezolid against GSE and GRE isolates were identical (2 mg/L), whereas the MIC 90 s of quinupristindalfopristin were 4 mg/L (GSE) and 2 mg/L (GRE). For E. faecalis, the MIC 90 s of GSE and GRE isolates of daptomycin (2 mg/L, 4 mg/L) and linezolid (2 mg/L, 2 mg/L) were similar.
There was an absence of correlation between the daptomycin zone diameters and MICs because of the unimodal MIC distribution for each species of organism tested (data not shown). Every S. aureus isolate (MICs ≤ 1 mg/L) had a daptomycin zone diameter ≥20 mm. The enterococcal isolates (MICs ≤ 4 mg/L) had daptomycin zone diameters ≥19 mm (E. faecalis) and ≥17 mm (E. faecium).
Discussion
In 1987, Jones & Barry 4 proposed daptomycin MIC and zone diameter breakpoints for susceptible Gram-positive isolates of ≤2 mg/L and ≥16 mm (resistant isolates: MIC, ≥8 mg/L; zone diameter, ≤12 mm) using media containing 50 mg/L Ca 2+ . Every staphylococcal, and 96.5% of the enterococcal isolates from the current study, had daptomycin MICs that would be classified as susceptible based on this tentative MIC breakpoint of ≤2 mg/L. If the previously proposed zone diameter breakpoint of ≥16 mm was applied, 4 
Wise et al. 6 noted that British Society for Antimicrobial Chemotherapy (BSAC) methodology would support a daptomycin MIC breakpoint of 4-8 mg/L for Gram-positive pathogens, but endorsed a breakpoint of ≤2 mg/L because few isolates had MICs above 2 mg/L. The same report proposed a zone diameter breakpoint of ≥20 mm and found only two isolates (E. faecium: MICs, 4 mg/L; zone diameters, 21 mm) of 328 Gram-positive organisms (0.6%) falsely susceptible.
King & Phillips 13 concluded that the ≥16 mm susceptible breakpoint was appropriate when using NCCLS methods, but proposed ≥18 mm for BSAC methods that employ an extra 1/10 or 1/100 inoculum dilution step (to yield semi-confluent growth) resulting in larger zones. King & Phillips 13 identified two enterococcal isolates with non-susceptible daptomycin MICs of 4 mg/L, but zone diameters larger than proposed zone breakpoints. Table 2 summarizes daptomycin susceptibility data obtained using 50 mg/L Ca 2+ for S. aureus and enterococci from five different studies, including the current report. Among the studies, no S. aureus isolate with a daptomycin MIC > 2 mg/L was described, and the activity of daptomycin against MRSA and MSSA was essentially the same (MIC 50 s and MIC 90 s no more than one dilution higher). For enterococci, GRE and GSE isolates were also inhibited by similar concentrations of daptomycin, but isolates with MICs as high as 8 mg/L were reported by one study. 5 An MIC breakpoint for the susceptible category other than ≤2 mg/L may be warranted for enterococci. Louie et al. 14 utilized a neutropenic mouse model of S. aureus thigh infection in order to study daptomycin activity, and concluded that the AUC/MIC ratio is the optimal pharmacodynamic parameter with which to predict outcome. A mouse model of enterococcal renal infection was used to demonstrate efficacy of daptomycin at doses producing AUCs of 400-600 mg·h/L against isolates with daptomycin MICs of ≤4 mg/L. 15 Based on these results, the following MIC interpretive criteria for enterococci have been proposed: susceptible, ≤4 mg/L; intermediate, 8 mg/L; resistant, ≥16 mg/L. 15 Overall, these in vitro studies document potent activity by daptomycin against isolates of enterococci and S. aureus, including GRE and MRSA, comparable with quinupristin-dalfopristin and linezolid. Definite interpretive criteria have not yet been established. The results of ongoing Phase III clinical trials are needed to establish firmly whether serious infections caused by staphylococcal isolates with daptomycin MICs ≤ 2 mg/L, and enterococcal isolates with daptomycin MICs ≤ 4 mg/L, can be treated effectively with this investigational lipopeptide antibiotic. Table 2 . In vitro activities of daptomycin against Staphylococcus aureus and Enterococcus faecium isolates reported by various studies using media containing calcium 50 mg/L
